- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
AG Professional reports that Isagro (BIT:ISG) and Arysta LifeScience have entered into a 15-year license, development, distribution and supply agreement, giving Arysta LifeScience exclusive global rights to develop mixtures of tetraconazole (a proprietary fungicide of Isagro) and fluoxastrobin (a proprietary fungicide of Arysta LifeScience) for all agricultural markets.
AG Professional reports thatĀ Isagro (BIT:ISG) and Arysta LifeScience have entered into a 15-year license, development, distribution and supply agreement, giving Arysta LifeScience exclusive global rights to develop mixtures of tetraconazole (a proprietary fungicide of Isagro) and fluoxastrobin (a proprietary fungicide of Arysta LifeScience) for all agricultural markets.
As quoted in the market news:
āThis agreement confirms the validity of tetraconazole as a long-term, sustainable partner for the development of new, high performance fungicides,ā said Giorgio Basile, Chairman and CEO, Isagro.
āWith Arysta LifeScienceās new formulations we will extend the market platform of our key product, for which Isagro has a worldwide program of investments.ā
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to theĀ cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Ā